Last reviewed · How we verify
NCT04612478
Use of a Self-Directed Exercise Program (SDEP) Following Selected Lower Extremity Fractures
NA trial testing Self-Directed Exercise Program in Musculoskeletal Injury in 150 participants. Completed in 2 November 2023.
2 November 2022
Quick facts
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 14 March 2018 |
| Primary completion | 2 November 2022 |
| Estimated completion | 2 November 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Self-Directed Exercise Program
- Clinic-Based Physical
Conditions studied
- Musculoskeletal Injury — all drugs for Musculoskeletal Injury →
Sponsor
Wake Forest University Health Sciences
Who can join
Adults 18 to 65, any sex, with Musculoskeletal Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare the effectiveness and value of clinic-based physical therapy (PT) and a home-based, self-directed exercise program (SDEP). The home exercise program will be developed by a team of physical therapists, orthopaedic trauma surgeons and experts in rehabilitation engagement in collaboration with patients recovering from traumatic lower-extremity injuries. The study will also determine which subgroups of individuals based on patient and injury characteristics are the best candidates for a home exercise program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04612478
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Musculoskeletal Injury
Currently open trials in the same condition.
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT06925503 — Mind-Body Conditioning Course for University Dance Students · NA · active not recruiting
- NCT05989230 — Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma · NA · recruiting
- NCT06455969 — Adaptions and Resiliency to Multi-Stressor OpeRations · Phase 4 · recruiting
- NCT06046859 — Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma? · Phase 4 · recruiting
Other Wake Forest University Health Sciences trials
Trials by the same sponsor.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04612478 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
- Last refreshed: 31 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04612478.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing